A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers

Phase 1 Completed 186 enrolled Denali Therapeutics Inc.

RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), and 28-day safety study of orally administered DNL151 in healthy volunteers.

Timeline

Start: 2017-11-16
Primary completion: 2021-02-19
Completion: 2021-02-19

Publications

Joshi D, Kulkarni M, Parekh P, Shah S, Greig NH, Acharya S. Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents. Nutr Neurosci. 2025 Dec;28(12):1532-1563. doi: 10.1080/1028415X.2025.2531356. Epub 2025 Jul 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIIB122	Small molecule	—	Oral

Indications

No indication recorded.